Embecta CORP 10-Q quarterly reports

Embecta Corp. reported a challenging third quarter for fiscal year 2026, with significant declines in revenue and gross profit, alongside increased costs, despite the strategic acquisition of Owen Mumford.

Embecta Corp. reported a revenue decrease for the second quarter of fiscal year 2026, alongside progress on its acquisition of Owen Mumford Holdings Limited.

Embecta Corp. reported a significant turnaround in net income for the first fiscal quarter of 2026, driven by substantial cost reductions and a strategic asset sale, despite flat revenues.

Embecta Corp. reports a significant increase in net income and operating profit for the third quarter, driven by cost reductions and strategic refocusing on its core diabetes care business.

Embecta Corp.'s Q2 2025 results reveal a revenue decrease, driven by volume declines and unfavorable foreign currency impacts, while the company continues to execute its restructuring plans.

Embecta Corp. reports a decrease in revenue and net income for the first quarter of fiscal year 2025, alongside the discontinuation of its patch pump program.

Embecta Corp. experienced a slight revenue decrease and a significant drop in operating income in the third quarter of 2024, while navigating ongoing business transitions and market pressures.

Embecta Corp. saw a revenue increase in the second quarter of 2024, but experienced a decrease in profitability due to rising costs and other factors.

Embecta Corp. experienced a slight revenue increase but a significant decrease in net income in the first quarter of fiscal year 2024, as it continues to navigate its transition as a standalone company.